Skip to main contentAI and Advanced
/
GVBL · BSEBSE SENSEX77,656.09+0.37%BSE |
NIFTY 5024,334.55+0.48%NSE |
NIFTY BANK57,514.2-0.02%NSE |
NIFTY IT30,771.8+0.57%NSE |
NIFTY AUTO29,216.9+0.40%NSE |
NIFTY FMCG47,706.95+0.38%NSE |
NIFTY PHARMA26,564+0.85%NSE |
NIFTY 50023,611.6+0.42%NSE |
GV
BSE · Equity shares · Biotechnology1.40 · 4.61%
Genomic Valley Biotech Ltd GVBL
NSE:Not available
BSE:INR 31.8
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsAvailable · provider snapshot
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for GVBL
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 30.4
Day rangeINR 30.5 — INR 31.85
52-week rangeINR 26.15 — INR 31.85
Volume380
Market cap9.71
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)0.04
Net Income (INR Cr)0.02
EPS0.05
Research path: Interpret Genomic Valley Biotech Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
GVBLGenomic Valley Biotech Ltd1d · INR · BSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
BSE reported results · INR crore
| Metric | Jun-26 | Mar-26 | FY25-26 |
|---|---|---|---|
| Revenue | 0.04 | 0.04 | 0.27 |
| Net Profit | 0.02 | -0.01 | 0.03 |
| EPS | 0.05 | -0.03 | 0.1 |
| Cash EPS | 0.05 | -0.02 | 0.11 |
| OPM % | 42.11 | 7.89 | 16.42 |
| NPM % | 39.47 | -21.05 | 11.19 |
Fundamentals
Valuation and ratios
Margins
Operating Margin 12m42.11
Net Profit Margin 12m39.47
Valuation
Price to Sale Ratio242.75
Risk and consensus
Source-qualified signals
Risk metrics
Risk metrics unavailable.
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
- Promoter and promoter group
- 46.06%
- Public shareholders
- 53.94%
- Other shareholders
- 0.00%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Announcement under Regulation 30 (LODR)-Newspaper PublicationBSE corporate filing · 17 Aug 2026, 5:30 am
Results-Financial Results For Quarter Ended On 30 June 2026.BSE corporate filing · 14 Aug 2026, 5:30 am
Board Meeting Outcome for Outcome Of The Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 Held On Today I.E. 14Th August 2026BSE corporate filing · 14 Aug 2026, 5:30 am
Board Meeting Intimation for Consideration And Approval Of Unaudited Financial Results (Standalone) Of The Company For The Quarter Ended On June 30, 2026BSE corporate filing · 6 Aug 2026, 5:30 am
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018BSE corporate filing · 6 Jul 2026, 5:30 am
Closure of Trading WindowBSE corporate filing · 29 Jun 2026, 5:30 am
Corporate actions
Events
- board MeetingsResults
- board MeetingsResults
- board MeetingsResults
- board MeetingsResults
- board MeetingsGeneral
- board MeetingsResults
- board MeetingsResults
- board MeetingsA.G.M.
ShareKeyX Community
Discussion and sentiment for Genomic Valley Biotech Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Not available
Company facts
- Industry
- Biotechnology
- Sector
- Healthcare
- Website
- www.genomicvalley.com
- Address
- 4 K.M. Stone, Berri Chharra Road, Village - Kherka Musalman, P.O. Tandaheri, Tehsil - Bahadurgarh, Dist. Jhajjar, Bahadurgarh, Haryana, 124507
- NSE Code
- GVBL
- BSE Code
- 539206
- Listing date
- 10 Jul 2015
- Face value
- 10
- Market lot
- 1
- CIN
- L01122HR1994PLC033029
- Company email
- genomicvalley@gmail.com
Leadership and officers
- Chairman, Managing Director & Chief Financial Officer
- Mr. YOGESH AGRAWAL
- Non - Executive Non -Independent Director
- Mrs. Parul Agrawal
- Non - Executive Independent Director
- Mr. Satendra Kumar Goyal
- Non-Executive - Independent Director
- Mr. Yogainder Kumar Gupta
- Company Secretary & Compliance Officer
- Mrs. Anupam Aditya
Questions
Stock FAQ
What is the symbol and ISIN of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has the symbol GVBL and ISIN - INE574D01010.
What is the current price of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd is currently trading at INR 31.80.
What are the year high and year low of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a year high of INR 31.85 and a year low of INR 26.15.
What is the market capitalization of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a market capitalization of INR 9.71 crore.
What is the P/E ratio of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a P/E ratio of NA.
What is the dividend yield of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a dividend yield of NA.
How is the financial performance of Genomic Valley Biotech Ltd based on revenue, net income, and EPS?
Genomic Valley Biotech Ltd has revenue of INR 0.04 crore, net income of INR 0.02 crore, and EPS of NA.
What is the book value of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a book value of NA.
What is the debt-to-equity ratio of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Genomic Valley Biotech Ltd?
Genomic Valley Biotech Ltd has a price-to-book ratio of NA and a price-to-sales ratio of 242.75.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.